Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...
TROY, NY, UNITED STATES, February 5, 2026 /EINPresswire.com/ — Inspect Point, the leading SaaS platform for fire and life safety inspection, testing, and compliance ...
Hosted on MSN
Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial
Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy ...
Dyne Therapeutics has announced a revised protocol for its ACHIEVE trial, elevating video hand opening time (vHOT) to the primary endpoint for U.S. Accelerated Approval of DYNE-101, a treatment for ...
The phase 3 study “A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants With Myotonic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results